Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers

Autor: Yoshihiko Yano, Hiroki Hayashi, Arata Sakai, Yuuki Shiomi, Eiichiro Yasutomi, Yoshihide Ueda, Kazutoshi Tobimatsu, Yuzo Kodama, Yuri Hatazawa, Ryutaro Yoshida, Naoki Asaji, Atsushi Yamamoto
Rok vydání: 2020
Předmět:
Zdroj: Journal of Cancer Research and Clinical Oncology. 147:1747-1756
ISSN: 1432-1335
0171-5216
DOI: 10.1007/s00432-020-03448-8
Popis: The risk factors and clinical characteristics of ICI-induced immune-mediated hepatotoxicity (IMH) are not fully understood. Thus, the present study sought to clarify the clinical features of IMH. All patients treated with ICIs between September 2014 and April 2019 at our institution were included. Clinical data were retrospectively collected from medical records. The frequency of grade ≥ 2 liver damage, clinical characteristics, and risk factors for developing IMH were examined. Overall, 250 patients (median age 71 years; range 30–87 years; 202 males and 48 females) were included in the analyses. Forty-five patients had elevated transaminase levels (> threefold the upper limit of normal). Of these, 21 were considered to have IMH. The remaining 24 patients had other causes of elevated transaminase levels. Steroids were administered to 13/21 patients with IMH. Although all patients exhibited improvement, IMH was not associated with the anticancer efficacy of the ICIs or OS. A multivariable analysis revealed that IMH was significantly associated with malignant melanoma (odds ratio [OR] 11.6; 95% confidence interval [CI] 3.5–38.0; P = 0.0002) and ipilimumab–nivolumab combination therapy (OR 61.2; 95% CI 7.9–1275.3; P
Databáze: OpenAIRE
Externí odkaz: